WO2026078647 - COMBINATION OF TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D AND CD3, AND POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
National phase entry is expected:
Publication Number
WO/2026/078647
Publication Date
16.04.2026
International Application No.
PCT/IB2025/060291
International Filing Date
10.10.2025
Title **
[English]
COMBINATION OF TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D AND CD3, AND POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
[French]
COMBINAISON D'UN ANTICORPS TRISPÉCIFIQUE CIBLANT BCMA, GPRC5D ET CD3 ET DE POMALIDOMIDE POUR LE TRAITEMENT DU MYÉLOME MULTIPLE
Applicants **
JANSSEN BIOTECH, INC.
Inventors
LEE, Sangmin
DASKALAKIS, Nikki
HILDER, Brandi Whitley
NGUYEN, Ashley
Priority Data
63/706,358
11.10.2024
US
63/738,238
23.12.2024
US
63/809,579
21.05.2025
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7327 | |
| EPO | Filing, Examination, Granting | 166872 | |
| Japan | Filing, Examination, Granting | 5220 | |
| South Korea | Filing, Examination, Granting | 11650 | |
| USA | Filing, Examination, Granting | 35690 |
Total:
226,759
Contact Us
Abstract[English]
Embodiments described herein relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of a BCMA x GPRC5D x CD3 trispecific antibody or trispecific binding fragment thereof, and pomalidomide, to the subject to treat the multiple myeloma.[French]
Des modes de réalisation de la présente invention concernent des méthodes de traitement du myélome multiple chez un sujet en ayant besoin, consistant à administrer au sujet une quantité thérapeutiquement efficace d'un anticorps trispécifique ciblant BCMA, GPRC5D et CD3, ou d'un fragment de liaison trispécifique de celui-ci, et de pomalidomide pour traiter le myélome multiple.